Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Jan;92(1):E11-E13.
doi: 10.1002/ajh.24594. Epub 2016 Nov 21.

Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma

Hui Yu  1 , Elena Sotillo  2 , Colleen Harrington  2   3 , Gerald Wertheim  1 , Michele Paessler  1 , Shannon L Maude  4   5 , Susan R Rheingold  4   5 , Stephan A Grupp  4   5 , Andrei Thomas-Tikhonenko  1   2   3 , Vinodh Pillai  1
Affiliations
Case Reports

Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma

Hui Yu et al. Am J Hematol. 2017 Jan.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Target antigen expression at various treatment time points.
CD20, CD30 and CD19 expression at diagnosis, post-rituximab or post-brentuximab/pre-CART19 and Post-CART19 infusion are shown. CD20 and CD30 are lost after rituximab and brentuximab respectively while CD19 expression changes after CART-19 therapy. The cytology and morphology of tumor was similar across the three time points.
Figure 2.
Figure 2.. Loss of membrane expression of CD19 post CART19 therapy.
CD19 immunostain and flow cytometric data from pre and post-CART therapy biopsies are shown. CD19 expression changes from strong membranous pattern to dim cytoplasm pattern (panel a). Flow cytometric evaluation of surface CD19 reveals loss of CD19 but intact CD20 after CART therapy (panel b).
See this image and copyright information in PMC

References

    1. Jacobsen ED, Sharman JP, Oki Y, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood 2015;125:1394–1402. - PubMed
    1. Maus MV, Grupp SA, Porter DL, et al. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014;123:2625–2635. - PMC - PubMed
    1. Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015;33:540–549. - PMC - PubMed
    1. de Miranda NF, Peng R, Georgiou K, et al. DNA repair genes are selectively mutated in diffuse large B cell lymphomas. J Exp Med 2013;210:1729–1742. - PMC - PubMed
    1. Perez-Callejo D, Gonzalez-Rincon J, Sanchez A, et al. Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas. Cancer Treat Rev 2015;41:680–689. - PubMed

Substances